This fourth and concluding part of the series reviews seven additional agents (Table 1) marketed in 2018: fostamatinib disodium hexahydrate (Tavalisse—Rigel), avatrombopag maleate (Doptelet—Dova), lusutrombopag (Mulpleta—Shionogi), patisiran (Onpattro—Alnylam), inotersen sodium (Tegsedi—Akcea, Ionis), moxnist such as eltrombopag (Promacta—Novartis) or romiplostim (Nplate—Amgen) has been used to increase platelet production.
At the completion of this activity, the participant will be able to:
- Identify the new therapeutic agents and explain their appropriate use.
- Identify the indications and mechanisms of action of the new agents.
- Identify the most important adverse events and other risks of the new therapeutic agents.
- State the route of administration for each new drug and the most important considerations for dosage and administration.
- Compare the new therapeutic agents with older medications to which they are most similar in properties and/or use, and identify their most imp
Activity type: Knowledge-based
Target Audience: Pharmacists
Learning level: 1
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-19-221-H01-P/T.
To obtain credit for New therapeutic agents marketed in 2018: Part 4, complete the assessment with a grade of 70% or better, complete the evaluation, and then claim credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA's continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and only two attempts to pass the assessment will be granted. The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: August 1, 2019
Expiration date: August 1, 2022 - NO CREDIT GRANTED AFTER THIS DATE
New therapeutic agents marketed in 2018: Part 4 is a home-study continuing education activity for pharmacists and pharmacy technicians developed by the American Pharmacists Association.
Mark S. Johnson, PharmD, BCPS, declares that he and his spouse hold stock in Merck & Co.
Daniel A. Hussar, PhD, FAPhA; Eric F. Hussar, MD;
There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.
Computer and internet access are required to complete this activity. Please visit our website and view the Technology System Requirements to have a positive learning experience.